Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.

Chaoyuan KuangYongseok ParkRyan C AugustinYan LinDouglas J HartmanLindsey SeighReetesh K PaiWeijing SunNathan BaharyJames OhrJohn C RheeStanley M MarksH Scott BeasleyYongli ShuaiJames G HermanHassane M ZarourEdward ChuJames J LeeAnuradha Krishnamurthy

Published in: Clinical epigenetics (2022)

The combination of pembrolizumab and azacitidine is safe and tolerable with modest clinical activity in the treatment for chemotherapy-refractory mCRC. Correlative studies suggest that tumor DNA demethylation and immunomodulation occurs. An association between tumor DNA demethylation and tumor-immune modulation suggests immune modulation and may result from treatment with azacitidine. Trial registration ClinicalTrials.gov, NCT02260440. Registered 9 October 2014, https://clinicaltrials.gov/ct2/show/NCT02260440 .

Keyphrases

acute myeloid leukemia
metastatic colorectal cancer
circulating tumor
clinical trial
single molecule
computed tomography
study protocol
locally advanced
radiation therapy
magnetic resonance imaging
contrast enhanced
phase iii
chemotherapy induced